Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity.
Although the use of tenofovir alafenamide (TAF), a new prodrug of tenofovir, was safe and efficacious in clinical trials, real-world data from multimorbid individuals are scarce. Among 10 persons living with HIV with previous tenofovir disoproxil fumarate-induced nephrotoxicity, renal function remained stable, and proteinuria decreased in several patients after the switch to TAF.
['Walti|Laura N|LN|', 'Steinrücken|Julia|J|', 'Rauch|Andri|A|', 'Wandeler|Gilles|G|']
tenofovir alafenamide antiretroviral therapy chronic kidney disease drug nephrotoxicity